Disulfide Bridging Conjugates

1 . An injectable formulation comprising:

(i) an effective amount of antibody Fab conjugate having a Formula I or a Formula II:

or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer from 2 to 20; each m is independently an integer from 2 to 15, wherein each FAB fragment is connected to a pyrrolidine-dione moiety or a CH 2 -quinoxalinyl moiety through native cysteine residues in the Fab fragment; and

(ii) water, Ringer's solution U.S.P., isotonic sodium chloride solution, synthetic mono- or diglycerides, or oleic acid.

2 . The injectable formulation of claim 1 , wherein n is an integer from 2 to 12.

3 . The injectable formulation of claim 2 , wherein n is an integer from 4 to 10.

4 . The injectable formulation of claim 3 , wherein n is 8.

5 . The injectable formulation of claim 1 , wherein m is an integer from 2 to 10.

6 . The injectable formulation of claim 5 , wherein m is an integer from 4 to 8.

7 . The injectable formulation of claim 6 , wherein m is 6.

8 . The injectable formulation of claim 1 , wherein the FAB fragment comprises a CD3 binding region.

9 . The injectable formulation of claim 1 , wherein the solvent is water.

10 . The injectable formulation of claim 1 , wherein the solvent is Ringer's solution U.S.P.

11 . The injectable formulation of claim 1 , wherein the solvent is an isotonic sodium chloride solution.

12 . The injectable formulation of claim 1 , wherein the solvent is a synthetic monoglyceride.

13 . The injectable formulation of claim 1 , wherein the solvent is a synthetic diglyceride.

14 . The injectable formulation of claim 1 , wherein the solvent is an oleic acid.

15 . A method of treating prostate cancer or adenocarcinoma, comprising administering to a subject in need thereof an injectable formulation of claim 1 , or a pharmaceutically acceptable salt thereof.

16 . The method of claim 15 , wherein the subject has prostate cancer.

17 . The method of claim 15 , wherein the subject has adenocarcinoma.